Skip to main content
SpringerLink
Log in
Book cover

Management of Urothelial Carcinoma pp 115–122Cite as

Multimodality Therapy

  • Chapter
  • First Online:

  • 523 Accesses

Abstract

Trimodality therapy (TMT) for localized muscle-invasive bladder cancer (MIBC) is a substitute for radical cystectomy. TMT consists of chemoradiation and transurethral resection of bladder tumor (TURB). The purpose of bladder preservation is to get advantage of quality of life and prevent morbidities of radical surgery with comparable oncologic outcomes. TMT could be considered not only for patients inappropriate for surgery but also for patients with MIBC who are reluctant to take surgery.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66:120–37.

    Article  CAS  Google Scholar 

  2. Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61:705–11.

    Article  Google Scholar 

  3. Horwich A, Dearnaley D, Huddart R, Graham J, Bessell E, Mason M, et al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol. 2005;75:34–43.

    Article  Google Scholar 

  4. Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol. 2011;29:733–8.

    Article  Google Scholar 

  5. Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 2009;27:4055–61.

    Article  CAS  Google Scholar 

  6. Foroudi F, Pham D, Bressel M, Wong J, Rolfo A, Roxby P, et al. Bladder cancer radiotherapy margins: a comparison of daily alignment using skin, bone or soft tissue. Clin Oncol. 2012;24:673–81.

    Article  CAS  Google Scholar 

  7. Gakis G, Efstathiou J, Lerner SP, et al. ICUD-EAU international consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63:45–57.

    Article  Google Scholar 

  8. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066–73.

    Article  Google Scholar 

  9. Shipley WU, Prout GR Jr, Einstein AB, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA. 1987;258:931–5.

    Article  CAS  Google Scholar 

  10. Tunio MA, Hashmi A, Qayyum A, Mohsin R, Zaeem A. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82:457–62.

    Article  Google Scholar 

  11. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20:3061–71.

    Article  Google Scholar 

  12. Hussain SA, Stocken DD, Peake DR, et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer. 2004;90:2106–11.

    Article  CAS  Google Scholar 

  13. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477–88. http://dx.doi.org/10.1056/NEJMoa1106106.

    Article  CAS  Google Scholar 

  14. Baxter E, Dennis K, Kollmannsberger C, Black P, Attwell A, Morris WJ, et al. Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experience. Urol Oncol. 2015;33:66.e13–9.

    Article  Google Scholar 

  15. Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Malek R, Kubler H, et al. A systemic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2018;36:43–53.

    Article  Google Scholar 

  16. Zapatero A, Martin De Vidales C, Arellano R, et al. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy. Urology. 2012;80:1056–62.

    Article  Google Scholar 

  17. Peyromaure M, Slama J, Beuzeboc P, Ponvert D, Debre´ B, Zerbib M. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution. Urology. 2004;63:73–7.

    Article  Google Scholar 

  18. Tilki D, Shariat SF, Lotan Y, et al. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int. 2013;111:1215–21.

    Article  Google Scholar 

  19. Watts KL, Ristau BT, Yamase HT, Taylor JA 3rd. Prognostic implications of lymph node involvement in bladder cancer: are we understaging using current methods? BJU Int. 2011;108:484–92.

    Article  Google Scholar 

  20. Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol. 2017;71(6):952–60. http://dx.doi.org/10.1016/j.eururo.2016.12.020.

  21. Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, et al. RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:665–72.

    Article  Google Scholar 

  22. Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys. 2007;68:1072–80.

    Article  CAS  Google Scholar 

  23. Onozawa M, Miyanaga N, Hinotsu S, Miyazaki J, Oikawa T, Kimura T, et al. Analysis of intravesical recurrence after bladder-preserving therapy for muscle-invasive bladder cancer. Jpn J Clin Oncol. 2012;42(9):825–30.

    Article  Google Scholar 

  24. Gogna NK, Matthews JH, Turner SL, Mameghan H, Duchesne GM, Spry N, et al. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol. 2006;81:9–17.

    Article  CAS  Google Scholar 

  25. Aboziada MA, Hamza HM, Abdlrahem AM. Initial results of bladder preserving approach by chemo-radiotherapy in patients with muscle invading transitional cell carcinoma. J Egypt Natl Canc Inst. 2009;21:167–74.

    PubMed  Google Scholar 

  26. Eswara JR, Efstathiou JA, Heney NM, Paly J, Kaufman DS, McDougal WS, et al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol. 2012;187:463–8.

    Article  Google Scholar 

  27. Iwai A, Koga F, Fujii Y, Masuda H, Saito K, Numao N, et al. Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder sparing protocol against muscle-invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy. Jpn J Clin Oncol. 2011;41:1373–9.

    Article  Google Scholar 

  28. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–75. https://doi.org/10.1200/jco.2001.19.3.666.

    Article  CAS  PubMed  Google Scholar 

  29. Dalbagni G, Genega E, Hashibe MIA, Zhang Z-F, Russo P, Herr H, et al. Cystectomy for bladder cancer: A contemporary series. J Urol. 2001;165(4):1111–6.

    Article  CAS  Google Scholar 

  30. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66. https://doi.org/10.1056/NEJMoa022148.

    Article  CAS  PubMed  Google Scholar 

  31. Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32(34):3801–9. https://doi.org/10.1200/jco.2014.57.5548.

    Article  Google Scholar 

  32. Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol. 2006;176:486–92.

    Article  Google Scholar 

  33. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al. Radical cystectomy for bladder cancer today–a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003;21:690–6.

    Article  Google Scholar 

  34. Azuma H, Yamamoto K, Inamoto T, Ibuki N, Kotake Y, Sakamoto T, et al. Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. Am J Clin Oncol. 2009;32:592–606.

    Article  CAS  Google Scholar 

  35. AlGizawy SM, Essa HH, Abdel-Wanis ME, Abdel Raheem AM. Trimodality bladdersparing approach versus radical cystectomy for invasive bladder cancer. J Radiother Pract. 2014;13:428–37.

    Article  Google Scholar 

  36. Zietman AL, Sacco D, Skowronski URI, Gomery P, Kaufman DS, Clark JA, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003;170:1772–6.

    Article  Google Scholar 

  37. Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng J-S, et al. Quality of life in long-term survivors of muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2016;96:1028–36.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Seoul National University Hospital, Seoul, South Korea

    Jung Hoon Lee, Jae Hyun Jung & Hyeong Dong Yuk

Authors
  1. Jung Hoon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jae Hyun Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hyeong Dong Yuk
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Seoul National University Hospital, Seoul, Korea (Republic of)

    Ja Hyeon Ku

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lee, J.H., Jung, J.H., Yuk, H.D. (2019). Multimodality Therapy. In: Ku, J. (eds) Management of Urothelial Carcinoma. Springer, Singapore. https://doi.org/10.1007/978-981-10-5502-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-5502-7_11

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-5501-0

  • Online ISBN: 978-981-10-5502-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation